GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

zansecimab   Click here for help

GtoPdb Ligand ID: 11334

Synonyms: LY-3127804 | LY3127804
Compound class: Antibody
Comment: Zansecimab (LY3127804) is a humanised IgG4 monoclonal antibody that targets angiopoietin 2 (Ang2). It was designed and developed by Eli Lilly to block angiogenesis as an anti-tumour mechanism. As Ang2 is elevated in acute respiratory distress syndrome (ARDS), Eli Lilly chose to evaluate LY3127804 in patients hospitalised with COVID-19 pneumonia, to ascertain if this approach could reduce the risk of developing ARDS in at risk patients. The COVID study was terminated for futility after around 6 months.
The peptide chain sequences of zansecimab (from its INN submission) are identical to sequences claimed in Eli Lilly's patent WO2015179166A1: sequences 2 and 4 comprise the heavy and light chains of the mAb designated as 'Antibody A' in the patent [1].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
angiopoietin-2 Primary target of this compound Hs Antibody Binding 11.0 pKd - 1
⤷ pKd 11.0 (Kd 1.1x10-11 M) [1]
Description: Binding affinity to human Ang2 measured using proprietary Kinetic Exclusion Assay (Kinexa®) methodology.